North America Gene Expression Market Report and Forecast 2025-2034
Description
North America gene expression market size was valued at USD 2.03 Billion in 2024, driven by the rapid advancement in the field of genomics in the region. The market is expected to grow at a CAGR of 8.50% during the forecast period of 2025-2034, with the values likely to rise from USD 4.59 Billion by 2034.
North America Gene Expression Market Analysis
The market growth is driven by advancements in gene expression analysis, which can help to define tumor subtypes and offer a more targeted approach towards cancer treatment. The rising incidence of cancer coupled with the growing patient inclination towards precision oncology is likely to augment market demand. In 2024, new cancer cases are projected to surpass 2 million in a year in the United States, with the estimates suggesting 5,500 cancer diagnoses in a day and over 611,000 deaths in the year. Insights from gene expression analysis can aid oncologists in providing tailored treatment to the huge patient population, thereby driving North America gene expression market growth.
In December 2023, Neurogene Inc., a United States-based biotechnology company specializing in genetic medicines, concluded a merger deal with Neoleukin Therapeutics, Inc., a biopharmaceutical company creating next-generation immunotherapies. The merged business, expected to hold cash worth USD 200 million on closure, plans to focus on the development of differentiated genetic therapies for the treatment of complex neurological diseases including Rett Syndrome. Such merger and acquisition activities are expected to propel the demand for gene expression analysis tools and services, which is likely to boost the market share in the region.
The market is witnessing technological innovations in DNA-sequencing and array-based technologies, which are anticipated to drive North America gene expression market demand. In March 2023, Illumina Inc., announced the launch of its new Illumina Complete Long Read technology called Illumina Complete Long Read Prep, Human. Designated as the first-ever product that allows access to both long- and short-read data on the same Illumina instrument, it is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing System. Illumina Complete Long Reads demonstrated accuracy and flexibility, as evidenced by early customer data. The launch of such technologically advanced products which address the limitations associated with long-read technologies and reduce associated costs is likely to support North America gene expression market share in the forecast period.
Other factors that drive the market are the increased application of gene expression profiling in understanding the molecular mechanisms in various diseases, biomarker discovery, drug development, and precision medicine, among others. Moreover, the advancement in healthcare infrastructure and increased investment in research and development are also expected to boost market size.
North America Gene Expression Market Segmentation
North America Gene Expression Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Breakup by Technology
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
North America Gene Expression Market Analysis
The market growth is driven by advancements in gene expression analysis, which can help to define tumor subtypes and offer a more targeted approach towards cancer treatment. The rising incidence of cancer coupled with the growing patient inclination towards precision oncology is likely to augment market demand. In 2024, new cancer cases are projected to surpass 2 million in a year in the United States, with the estimates suggesting 5,500 cancer diagnoses in a day and over 611,000 deaths in the year. Insights from gene expression analysis can aid oncologists in providing tailored treatment to the huge patient population, thereby driving North America gene expression market growth.
In December 2023, Neurogene Inc., a United States-based biotechnology company specializing in genetic medicines, concluded a merger deal with Neoleukin Therapeutics, Inc., a biopharmaceutical company creating next-generation immunotherapies. The merged business, expected to hold cash worth USD 200 million on closure, plans to focus on the development of differentiated genetic therapies for the treatment of complex neurological diseases including Rett Syndrome. Such merger and acquisition activities are expected to propel the demand for gene expression analysis tools and services, which is likely to boost the market share in the region.
The market is witnessing technological innovations in DNA-sequencing and array-based technologies, which are anticipated to drive North America gene expression market demand. In March 2023, Illumina Inc., announced the launch of its new Illumina Complete Long Read technology called Illumina Complete Long Read Prep, Human. Designated as the first-ever product that allows access to both long- and short-read data on the same Illumina instrument, it is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing System. Illumina Complete Long Reads demonstrated accuracy and flexibility, as evidenced by early customer data. The launch of such technologically advanced products which address the limitations associated with long-read technologies and reduce associated costs is likely to support North America gene expression market share in the forecast period.
Other factors that drive the market are the increased application of gene expression profiling in understanding the molecular mechanisms in various diseases, biomarker discovery, drug development, and precision medicine, among others. Moreover, the advancement in healthcare infrastructure and increased investment in research and development are also expected to boost market size.
North America Gene Expression Market Segmentation
North America Gene Expression Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Breakup by Technology
- Polymerase Chain Reaction
- Next Generation Sequencing
- Microarrays
- Northern Blotting
- Others
- Instruments
- Reagents and Consumables
- Services
- Drug Discovery & Development Centers
- Diagnostic Laboratories
- Academic Research Centers
- Others
- United States of America
- Canada
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific Inc.
- GE Healthcare
- QIAGEN N.V.
- Life Technologies
- Agilent Technologies
- PerkinElmer
- Bio-Rad Laboratories
- Roche Diagnostics
- Oxford Gene Technology
- Luminex Corporation
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 North America Gene Expression Market Overview
- 3.1 North America Gene Expression Market Historical Value (2018-2024)
- 3.2 North America Gene Expression Market Forecast Value (2025-2034)
- 4 North America Gene Expression Market Landscape*
- 4.1 North America Gene Expression: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 North America Gene Expression: Product Landscape
- 4.2.1 Analysis by Technology
- 4.2.2 Analysis by Product Type
- 5 North America Gene Expression Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 North America Gene Expression Market Segmentation (218-2034)
- 6.1 North America Gene Expression Market (2018-2034) by Technology
- 6.1.1 Market Overview
- 6.1.2 Polymerase Chain Reaction
- 6.1.3 Next Generation Sequencing
- 6.1.4 Microarrays
- 6.1.5 Northern Blotting
- 6.1.6 Others
- 6.2 North America Gene Expression Market (2018-2034) by Product Type
- 6.2.1 Market Overview
- 6.2.2 Instruments
- 6.2.3 Reagents and Consumables
- 6.2.4 Services
- 6.3 North America Gene Expression Market (2018-2034) by End User
- 6.3.1 Market Overview
- 6.3.2 Drug Discovery & Development Centers
- 6.3.3 Diagnostic Laboratories
- 6.3.4 Academic Research Centers
- 6.3.5 Others
- 6.4 North America Gene Expression Market (2018-2034) by Countries
- 6.4.1 Market Overview
- 6.4.2 United States of America
- 6.4.3 Canada
- 7 United States of America Gene Expression Market (218-2034)
- 7.1 United States of America Gene Expression Market (2018-2034) by Technology
- 7.1.1 Market Overview
- 7.1.2 Polymerase Chain Reaction
- 7.1.3 Next Generation Sequencing
- 7.1.4 Microarrays
- 7.1.5 Northern Blotting
- 7.1.6 Others
- 7.2 United states of America Gene Expression Market (2018-2034) by Product Type
- 7.2.1 Market Overview
- 7.2.2 Instruments
- 7.2.3 Reagents and Consumables
- 7.2.4 Services
- 7.2.5 Others
- 7.3 United States of America Gene Expression Market (2018-2034) by End User
- 7.3.1 Market Overview
- 7.3.2 Drug Discovery & Development Centers
- 7.3.3 Diagnostic Laboratories
- 7.3.4 Academic Research Centers
- 8 Canada Gene Expression Market (218-2034)
- 8.1 Canada Gene Expression Market (2018-2034) by Technology
- 8.1.1 Market Overview
- 8.1.2 Polymerase Chain Reaction
- 8.1.3 Next Generation Sequencing
- 8.1.4 Microarrays
- 8.1.5 Northern Blotting
- 8.1.6 Others
- 8.2 Canada Gene Expression Market (2018-2034) by Product Type
- 8.2.1 Market Overview
- 8.2.2 Instruments
- 8.2.3 Reagents and Consumables
- 8.2.4 Services
- 8.2.5 Others
- 8.3 Canada Gene Expression Market (2018-2034) by End User
- 8.3.1 Market Overview
- 8.3.2 Drug Discovery & Development Centers
- 8.3.3 Diagnostic Laboratories
- 8.3.4 Academic Research Centers
- 9 Regulatory Framework
- 10 Patent Analysis
- 10.1 Analysis by Type of Patent
- 10.2 Analysis by Publication year
- 10.3 Analysis by Issuing Authority
- 10.4 Analysis by Patent Age
- 10.5 Analysis by CPC Analysis
- 10.6 Analysis by Patent Valuation
- 10.7 Analysis by Key Players
- 11 Funding and Investment Analysis
- 11.1 Analysis by Funding Instances
- 11.2 Analysis by Type of Funding
- 11.3 Analysis by Funding Amount
- 11.4 Analysis by Leading Players
- 11.5 Analysis by Leading Investors
- 11.6 Analysis by Geography
- 12 Partnership and Collaborations Analysis
- 12.1 Analysis by Partnership Instances
- 12.2 Analysis by Type of Partnership
- 12.3 Analysis by Leading Players
- 12.4 Analysis by Geography
- 13 Supplier Landscape
- 13.1 Market Share by Top 5 Companies
- 13.2 Thermo Fisher Scientific Inc.
- 13.2.1 Financial Analysis
- 13.2.2 Product Portfolio
- 13.2.3 Demographic Reach and Achievements
- 13.2.4 Mergers and Acquisitions
- 13.2.5 Certifications
- 13.3 GE Healthcare
- 13.3.1 Financial Analysis
- 13.3.2 Product Portfolio
- 13.3.3 Demographic Reach and Achievements
- 13.3.4 Mergers and Acquisitions
- 13.3.5 Certifications
- 13.4 QIAGEN N.V.
- 13.4.1 Financial Analysis
- 13.4.2 Product Portfolio
- 13.4.3 Demographic Reach and Achievements
- 13.4.4 Mergers and Acquisitions
- 13.4.5 Certifications
- 13.5 Life Technologies
- 13.5.1 Financial Analysis
- 13.5.2 Product Portfolio
- 13.5.3 Demographic Reach and Achievements
- 13.5.4 Mergers and Acquisitions
- 13.5.5 Certifications
- 13.6 Agilent Technologies
- 13.6.1 Financial Analysis
- 13.6.2 Product Portfolio
- 13.6.3 Demographic Reach and Achievements
- 13.6.4 Mergers and Acquisitions
- 13.6.5 Certifications
- 13.7 PerkinElmer
- 13.7.1 Financial Analysis
- 13.7.2 Product Portfolio
- 13.7.3 Demographic Reach and Achievements
- 13.7.4 Mergers and Acquisitions
- 13.7.5 Certifications
- 13.8 Bio-Rad Laboratories
- 13.8.1 Financial Analysis
- 13.8.2 Product Portfolio
- 13.8.3 Demographic Reach and Achievements
- 13.8.4 Mergers and Acquisitions
- 13.8.5 Certifications
- 13.9 Roche Diagnostics
- 13.9.1 Financial Analysis
- 13.9.2 Product Portfolio
- 13.9.3 Demographic Reach and Achievements
- 13.9.4 Mergers and Acquisitions
- 13.9.5 Certifications
- 13.10 Oxford Gene Technology
- 13.10.1 Financial Analysis
- 13.10.2 Product Portfolio
- 13.10.3 Demographic Reach and Achievements
- 13.10.4 Mergers and Acquisitions
- 13.10.5 Certifications
- 13.11 Luminex Corporation
- 13.11.1 Financial Analysis
- 13.11.2 Product Portfolio
- 13.11.3 Demographic Reach and Achievements
- 13.11.4 Mergers and Acquisitions
- 13.11.5 Certifications
- 14 North America Gene Expression Market – Distribution Model (Additional Insight)
- 14.1 Overview
- 14.2 Potential Distributors
- 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
- 16.1 Very Small Companies
- 16.2 Small Companies
- 16.3 Mid-Sized Companies
- 16.4 Large Companies
- 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
- 17.1 Government Funded
- 17.2 Private Insurance
- 17.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
